- Home
- PHAR vs DXYZ Comparison
PHAR vs DXYZ Comparison
Compare PHAR & DXYZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- DXYZ
- Stock Information
- Founded
- PHAR 1988
- DXYZ N/A
- Country
- PHAR Netherlands
- DXYZ
- Employees
- PHAR N/A
- DXYZ N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- DXYZ
- Sector
- PHAR Health Care
- DXYZ
- Exchange
- PHAR Nasdaq
- DXYZ Nasdaq
- Market Cap
- PHAR 951.7M
- DXYZ 313.1M
- IPO Year
- PHAR N/A
- DXYZ 2024
- Fundamental
- Price
- PHAR $14.60
- DXYZ $25.83
- Analyst Decision
- PHAR Strong Buy
- DXYZ
- Analyst Count
- PHAR 3
- DXYZ 0
- Target Price
- PHAR $30.00
- DXYZ N/A
- AVG Volume (30 Days)
- PHAR 12.7K
- DXYZ N/A
- Earning Date
- PHAR 10-23-2025
- DXYZ N/A
- Dividend Yield
- PHAR N/A
- DXYZ N/A
- EPS Growth
- PHAR N/A
- DXYZ N/A
- EPS
- PHAR N/A
- DXYZ N/A
- Revenue
- PHAR $339,836,000.00
- DXYZ N/A
- Revenue This Year
- PHAR $16.63
- DXYZ N/A
- Revenue Next Year
- PHAR $6.77
- DXYZ N/A
- P/E Ratio
- PHAR N/A
- DXYZ N/A
- Revenue Growth
- PHAR 22.44
- DXYZ N/A
- 52 Week Low
- PHAR $7.31
- DXYZ N/A
- 52 Week High
- PHAR $17.08
- DXYZ N/A
- Technical
- Relative Strength Index (RSI)
- PHAR 56.71
- DXYZ 36.40
- Support Level
- PHAR $13.63
- DXYZ $26.00
- Resistance Level
- PHAR $15.27
- DXYZ $27.95
- Average True Range (ATR)
- PHAR 0.96
- DXYZ 0.92
- MACD
- PHAR -0.13
- DXYZ 0.16
- Stochastic Oscillator
- PHAR 51.83
- DXYZ 8.75
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About DXYZ Destiny Tech100 Inc. Common Stock
Destiny Tech100 Inc is a non-diversified, closed-end management investment company. It invests in a portfolio of what is believed to be 100 of the top venture-backed private technology companies.